Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2004 Mar;65(2):172–184. doi: 10.1016/S0011-393X(04)90031-8

Blood pressure control and weight loss in overweight or obese patients with previously treated or untreated mild to moderate hypertension given valsartan: An open-label study comparing pretreatment and posttreatment values

Aldo S Villecco 1,∗, Cinzia Cocci 1, Maurizio Di Emidio 1
PMCID: PMC4052971  PMID: 24936115

Abstract

Background: Hypertension is associated with obesity. Recent studies have indicated that therapy with an angiotensin II antagonist, in addition to having an antihypertensive effect, may cause a reduction in body weight.

Objective: The aim of this study was to assess the efficacy and tolerability of valsartan in the treatment of overweight or obese patients with mild to moderate essential hypertension.

Methods: Overweight or obese outpatients aged 18 to <70 years with previously treated or untreated mild to moderate essential hypertension were eligible for this open-label study conducted at the Department of Internal Medicine and Aging, Clinica Medica II, Policlinico S. Orsola-Malpighi (Bologna, Italy). After a 1-week pharmacologic washout period, patients were treated with valsartan capsules at a fixed dosage of 80 mg once daily for 8 weeks. The dosage was increased to 160 mg once daily if, at 8 weeks, diastolic blood pressure (DBP) was not normalized; otherwise, the 80-mg/d dosage was maintained. Treatment was continued for an additional 16 weeks. Patients' heart rate, systolic blood pressure (SBP) and DBP, body mass index (BMI), and waist-hip ratio (WHR) were measured/calculated at baseline (week 0) and 8, 16, and 24 weeks. Patients were asked to maintain a 1600-kcal/d diet throughout the study.

Results: Forty-eight patients (28 men, 20 women; mean [SD] age, 57 [9] years) were included in the study. In the 45 patients (93.8%) who completed the study, mean SBP, DBP, and BMI were significantly decreased compared with baseline (all P < 0.001), but WHR was significantly increased (P < 0.05). After 24 weeks of treatment, 71.1 % of patients had SBP/DBP ≤ 140/≤90 mm Hg. Three patients (6.3%) withdrew from the study due to treatment-related adverse events.

Conclusion: In this population of overweight or obese patients with mild to moderate hypertension, valsartan was well tolerated, and could be effective in controlling blood pressure and achieving weight loss in such patients.

Keywords: angiotensin II antagonist, mild to moderate hypertension, obesity

Full Text

The Full Text of this article is available as a PDF (104.3 KB).

References

  • 1.Chiang B.N., Perlman L.V., Epstein F.H. Overweight and hypertension. A review. Circulation. 1969;39:403–421. doi: 10.1161/01.cir.39.3.403. [DOI] [PubMed] [Google Scholar]
  • 2.Krieger D.R., Landsberg L. Obesity and hypertension. In: Laragh J.H., Brenner B.M., editors. Hypertension: Pathophysiology, Diagnosis, and Management. 2nd ed. Raven Press; New York, NY: 1995. pp. 2367–2388. [Google Scholar]
  • 3.MacMahon S., Cutler J., Brittain E., Higgins M. Obesity and hypertension: Epidemiological and clinical issues. Eur Heart J. 1987;8(Suppl B):57–70. doi: 10.1093/eurheartj/8.suppl_b.57. [DOI] [PubMed] [Google Scholar]
  • 4.Hall J.E., Brands M.W., Dixon W.N., Smith M.J., Jr. Obesity-induced hypertension: Renal function and systemic hemodynamics. Hypertension. 1993;22:292–299. doi: 10.1161/01.hyp.22.3.292. [DOI] [PubMed] [Google Scholar]
  • 5.Sharma A.M., Engeli S., Pischon T. New developments in mechanism of obesityinduced hypertension: Role of adipose tissue. Curr Hypertens Rep. 2001;3:152–156. doi: 10.1007/s11906-001-0030-x. [DOI] [PubMed] [Google Scholar]
  • 6.Kopelman P.G. Obesity as a medical problem. Nature. 2000;404:635–643. doi: 10.1038/35007508. [DOI] [PubMed] [Google Scholar]
  • 7.Reisin E., Abel R., Modan M. Effect of weight loss without salt restriction on the reduction of blood pressure in overweight hypertensive patients. N Engl J Med. 1978;298:1–6. doi: 10.1056/NEJM197801052980101. [DOI] [PubMed] [Google Scholar]
  • 8.Rocchini A.P., Key J., Bondie D. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med. 1989;321:580–585. doi: 10.1056/NEJM198908313210905. [DOI] [PubMed] [Google Scholar]
  • 9.Rocchini A.P. Insulin resistance and blood pressure regulation in obese and nonobese subjects. Hypertension. 1991;17:837–842. doi: 10.1161/01.hyp.17.6.837. [DOI] [PubMed] [Google Scholar]
  • 10.Unger T., Gohlke P. Tissue renin-angiotensin systems in the heart and vasculature: Possible involvement in the cardiovascular actions of converting enzyme inhibitors. Am J Cardiol. 1990;65:31–101. doi: 10.1016/0002-9149(90)90118-k. [DOI] [PubMed] [Google Scholar]
  • 11.Lee M.A., Bohm M., Paul M., Ganten D. Tissue renin-angiotensin systems. Their role in cardiovascular disease. Circulation. 1993;87(Suppl 5):IV7, IV13. [PubMed] [Google Scholar]
  • 12.Kim S., Moustaid-Moussa N. Secretory, endocrine and autocrine/paracrine function of the adipocyte. J Nutr. 2000;130:31105–31155. doi: 10.1093/jn/130.12.3110S. [DOI] [PubMed] [Google Scholar]
  • 13.Faloia E., Camilloni M.A., Giacchetti G., Mantero F. Adipose tissue as an endocrine organ? A review of some recent data. Eat Weight Disord. 2000;5:116–123. doi: 10.1007/BF03354441. [DOI] [PubMed] [Google Scholar]
  • 14.Frederich R.C., Jr, Kahn B.B., Peach M.J., Flier J.S. Tissue-specific nutritional regulation of angiotensinogen in adipose tissue. Hypertension. 1992;19:339–344. doi: 10.1161/01.hyp.19.4.339. [DOI] [PubMed] [Google Scholar]
  • 15.Harp J.B., DiGirolamo M. Components of the renin-angiotensin system in adipose tissue: Changes with maturation and adipose mass enlargement. J Gerontol A Biol Sci Med Sci. 1995;50:B270–B276. doi: 10.1093/gerona/50a.5.b270. [DOI] [PubMed] [Google Scholar]
  • 16.Karlsson C., Lindell K., Ottosson M. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin 11. J Clin Endocrinol Metab. 1998;83:3925–3929. doi: 10.1210/jcem.83.11.5276. [DOI] [PubMed] [Google Scholar]
  • 17.Engeli S., Negrel R., Sharma A.M. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension. 2000;35:1270–1277. doi: 10.1161/01.hyp.35.6.1270. [DOI] [PubMed] [Google Scholar]
  • 18.Ailhaud G., Fukamizu A., Massiera F. Angiotensinogen, angiotensin II and adipose tissue development. Int J Obes Relat Metab Disord. 2000;24(Suppl 4):S33–S35. doi: 10.1038/sj.ijo.0801501. [DOI] [PubMed] [Google Scholar]
  • 19.Cooper R., McFarlane-Anderson N., Bennett Fl. ACE, angiotensinogen and obesity: A potential pathway leading to hypertension. J Hum Hypertens. 1997;11:107–111. doi: 10.1038/sj.jhh.1000391. [DOI] [PubMed] [Google Scholar]
  • 20.Umemura S., Nyui N., Tamura K. Plasma angiotensinogen concentrations in obese patients. Am J Hyperteas. 1997;10:629–633. doi: 10.1016/s0895-7061(97)00053-8. [DOI] [PubMed] [Google Scholar]
  • 21.Ernsberger P., Koletsky R.J., Baskin J.S., Foley M. Refeeding hypertension in obese spontaneously hypertensive rats. Hypertension. 1994;24:699–705. doi: 10.1161/01.hyp.24.6.699. [DOI] [PubMed] [Google Scholar]
  • 22.Ernsberger P., Koletsky R.J., Baskin J.S., Collins L.A. Consequences of weight cycling in obese spontaneously hypertensive rats. Am J Physiol. 1996;270:R864–R872. doi: 10.1152/ajpregu.1996.270.4.R864. [DOI] [PubMed] [Google Scholar]
  • 23.Contreras R.J., King S., Rives L. Dietary obesity and weight cycling in rats: A model of stress-induced hypertension? Am J Physiol. 1991;261:R848–R857. doi: 10.1152/ajpregu.1991.261.4.R848. [DOI] [PubMed] [Google Scholar]
  • 24.Eckel R.H., Krauss R.M., American Heart Association Nutrition Committee American Heart Association call to action: Obesity as a major risk factor for coronary heart disease. Circulation. 1998;97:2099–2100. doi: 10.1161/01.cir.97.21.2099. [DOI] [PubMed] [Google Scholar]
  • 25.National Task Force on the Prevention and Treatment of Obesity Overweight, obesity, and health risk. Arch Intern Med. 2000;160:898–904. doi: 10.1001/archinte.160.7.898. [DOI] [PubMed] [Google Scholar]
  • 26.Reaven G.M., Lithell H., Landsberg L. Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996;334:374–381. doi: 10.1056/NEJM199602083340607. [DOI] [PubMed] [Google Scholar]
  • 27.Al Suwaidi J., Higano S.T., Hamasaki S. Association between obesity and coronary atherosclerosis and vascular remodeling. Am J Cardiol. 2001;88:1300–1303. doi: 10.1016/s0002-9149(01)02093-8. [DOI] [PubMed] [Google Scholar]
  • 28.Oparil S., Dyke S., Harris F. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther. 1996;18:797–810. doi: 10.1016/s0149-2918(96)80040-3. [DOI] [PubMed] [Google Scholar]
  • 29.Benz J., Oshrain C., Henry D. Valsartan, a new angiotensin II receptor antagonist: A double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol. 1997;37:101–107. doi: 10.1002/j.1552-4604.1997.tb04767.x. [DOI] [PubMed] [Google Scholar]
  • 30.Struthers A.D. Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J. 1995;16(Suppl N):103–106. doi: 10.1093/eurheartj/16.suppl_n.103. [DOI] [PubMed] [Google Scholar]
  • 31.Villecco A.S., de Aloysio D., Radi D. Plasma catecholamines in pre- and postmenopausal women with mild to moderate essential hypertension. J Hum Hypertens. 1997;11:157–162. doi: 10.1038/sj.jhh.1000411. [DOI] [PubMed] [Google Scholar]
  • 32.The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood PressureArch Intern Med. 1997;157:2413–2446. doi: 10.1001/archinte.157.21.2413. [DOI] [PubMed] [Google Scholar]
  • 33.Garrow J.S., Webster J. Quetelet's index (W/HZ) as measure of fatness. Int J Obes. 1985;9:147–153. [PubMed] [Google Scholar]
  • 34.Crepaldi G., Belfiore S., Bosello O. Italian Consensus Conference-overweight, obesity and health. Int J Obes. 1991;15:781–790. [PubMed] [Google Scholar]
  • 35.Duncan D.B. Multiple range test for correlated and heteroscedastic means. Biometrika. 1957;13:164–204. [Google Scholar]
  • 36.Elliott W.J., Calhoun D.A., DeLucca P.T. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: Data from a multicenter, randomized, double-blind, 12-week trial. Clin Ther. 2001;23:1166–1179. doi: 10.1016/s0149-2918(01)80099-0. [DOI] [PubMed] [Google Scholar]
  • 37.Benedict C.R. Safe and effective management of hypertension with fixed-dose combination therapy: Focus on losartan plus hydrochlorothiazide. Int J Clin Pract. 2000;54:48–54. [PubMed] [Google Scholar]
  • 38.Conlin P.R., Spence J.D., Williams B. Angiotensin II antagonists for hypertension: Are there differences in efficacy? Am J Hyperteas. 2000;13:418–426. doi: 10.1016/s0895-7061(99)00237-x. [DOI] [PubMed] [Google Scholar]
  • 39.Grassi G., Seravalle G., Dell'Oro R. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: Results of the CROSS study. J Hyperteas. 2003;21:1761–1769. doi: 10.1097/00004872-200309000-00027. [DOI] [PubMed] [Google Scholar]
  • 40.Klein S. Outcome success in obesity. Obes Res. 2001;9(Suppl 4):3545–3585. doi: 10.1038/oby.2001.142. [DOI] [PubMed] [Google Scholar]
  • 41.Massiera F., Bloch-Faure M., Ceiler D. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure. FASEB J. 2001;15:2727–2729. doi: 10.1096/fj.01-0457fje. [DOI] [PubMed] [Google Scholar]
  • 42.Janke J., Engeli S., Gorzelniak K. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes. 2002;51:1699–1707. doi: 10.2337/diabetes.51.6.1699. [DOI] [PubMed] [Google Scholar]
  • 43.Giacchetti G., Faloia E., Mariniello B. Overexpression of the renin-angiotensin system in human visceral adipose tissue in normal and overweight subjects. Am J Hyperteas. 2002;15:381–388. doi: 10.1016/s0895-7061(02)02257-4. [DOI] [PubMed] [Google Scholar]
  • 44.Lafontan M., Sengenes C., Galitzky J. Recent developments on lipolysis regulation in humans and discovery of a new lipolytic pathway. Int J Obes Relat Metab Disord. 2000;24(Suppl 4):S47–S52. doi: 10.1038/sj.ijo.0801505. [DOI] [PubMed] [Google Scholar]
  • 45.Castan-Laurell I., Boucher J., Rey A. Development of nutritional obesity in transgenic mice with an adrenergic receptivity in adipose tissue comparable with that of humans. Path Biol (Paris) 2002;50:52–57. doi: 10.1016/s0369-8114(01)00268-1. [in French] [DOI] [PubMed] [Google Scholar]
  • 46.Boschmann M., Ringel J., Klaus S., Sharma A.M. Metabolic and hemodynamic response of adipose tissue to angiotensin II. Obes Res. 2001;9:486–491. doi: 10.1038/oby.2001.63. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES